PharmTech LCGC Sciex Webinar 11.10
|Articles|October 8, 2019

Column

  • The Column-10-08-2019
  • Volume 15
  • Issue 10

Thermo and Cedar-Sinai Announce Collaboration

Thermo Fisher Scientific and Cedars-Sinai have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive LC–MS-based workflows for clinical research applications.

Thermo Fisher Scientific (Waltham, Massachusetts, USA) and Cedars-Sinai (Los Angeles, California, USA) have announced a collaboration to develop a pathway to precision medicine through the development of robust, reliable, and sensitive liquid chromatography–mass spectrometry (LC–MS)-based workflows for clinical research applications.

“Thermo Fisher shares our vision for helping clinical research teams set new standards for excellence and innovation in patient care through precision medicine. The goal is to develop advanced
LC–MS‑based workflows for the untargeted screening and targeted quantitation of protein-based biomarkers for critical disease states, which hold the potential to benefit not only our own patients but also the wider clinical community,” said Jennifer Van Eyk, Ph.D., Principal Investigator for Research and Director of the Advanced Clinical Biosystems Institute in the Department of Biomedical Sciences at Cedars-Sinai.

For more information, please visit www.thermofisher.com/BeSure

 

 

 


Related to this article

Best of the Week: From Cancer Diagnostics to Smarter LC Method Development
This week, Chromatography Online’s coverage spanned lipidomics-based early cancer detection, career paths in separation science, machine learning and uncertainty-driven approaches to LC method development, new EU wastewater rules for pharmaceutical micropollutants, automated Separation Quality Factor (SQF) evaluation in chromatography data systems, and solutions to GLP-1 peptide analysis challenges.